Literature DB >> 29576326

Remission in CBT for adult anxiety disorders: A meta-analysis.

Kristen S Springer1, Hannah C Levy1, David F Tolin2.   

Abstract

Currently there is no universally accepted definition of remission in anxiety disorders. This may be causing significantly different estimates of treatment efficacy across anxiety disorders. The aim of this paper was to determine not only the overall remission rate in cognitive-behavioral therapy (CBT) for anxiety disorders, but also to examine whether the different definitions of remission lead to significantly different remission rates. From the initial 228 abstracts reviewed by the authors, 100 articles were retained. The overall mean remission rate was 51.0%. Remission rates were highest when remission was defined as good end state functioning or no longer meeting criteria for the primary diagnosis. Studies of posttraumatic stress disorder had the highest remission rates, while those of obsessive-compulsive disorder and social anxiety disorder had the lowest remission rates. Rates of remission differed by certain demographic (e.g., older age) and clinical (e.g., medication use) characteristics. Although CBT is an empirically supported treatment for anxiety disorders, it is clear that there is room for improvement, as many patients do not achieve remission status.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anxiety; CBT; Meta-analysis; OCD; PTSD; Remission

Mesh:

Year:  2018        PMID: 29576326     DOI: 10.1016/j.cpr.2018.03.002

Source DB:  PubMed          Journal:  Clin Psychol Rev        ISSN: 0272-7358


  28 in total

1.  Effectiveness of Briefer Coping-Focused Psychotherapy for Common Mental Complaints on Work-Participation and Mental Health: A Pragmatic Randomized Trial with 2-Year Follow-Up.

Authors:  M E A Wormgoor; A Indahl; E Andersen; J Egeland
Journal:  J Occup Rehabil       Date:  2020-03

2.  Estimating outcome probabilities from early symptom changes in cognitive therapy for recurrent depression.

Authors:  Jeffrey R Vittengl; Lee Anna Clark; Michael E Thase; Robin B Jarrett
Journal:  J Consult Clin Psychol       Date:  2019-04-22

3.  Using Transdiagnostic Mechanistic Targets to Advance Prevention Science.

Authors:  Emily M O'Bryan; Kristen M Kraemer; Alison C McLeish
Journal:  Clin Psychol (New York)       Date:  2021-12

Review 4.  The prefrontal cortex, pathological anxiety, and anxiety disorders.

Authors:  Margaux M Kenwood; Ned H Kalin; Helen Barbas
Journal:  Neuropsychopharmacology       Date:  2021-08-16       Impact factor: 8.294

5.  The psychological and subjective experience of catatonia: a qualitative study.

Authors:  Zukiswa Zingela; Louise Stroud; Johan Cronje; Max Fink; Stephan van Wyk
Journal:  BMC Psychol       Date:  2022-07-15

6.  A Case for Translation From the Clinic to the Laboratory.

Authors:  M Alexandra Kredlow; Lycia D de Voogd; Elizabeth A Phelps
Journal:  Perspect Psychol Sci       Date:  2022-03-04

7.  Blocking the orexin system following therapeutic exposure promoted between session habituation, but not PTSD symptom reduction.

Authors:  Ihori Kobayashi; Thomas A Mellman; Ashley Cannon; Imani Brown; Linda Boadi; Mary Katherine Howell; Pewu Lavela; Ishaan Sandhu
Journal:  J Psychiatr Res       Date:  2021-12-14       Impact factor: 5.250

8.  Feasibility and acceptability of an enhanced cognitive behavioural therapy programme for parent-child dyads with anxiety disorders: a mixed-methods pilot trial protocol.

Authors:  Samantha Galea; Chloe A Salvaris; Marie B H Yap; Peter J Norton; Katherine A Lawrence
Journal:  Pilot Feasibility Stud       Date:  2021-05-17

9.  Study quality and efficacy of psychological interventions for posttraumatic stress disorder: a meta-analysis of randomized controlled trials.

Authors:  Nexhmedin Morina; Thole H Hoppen; Ahlke Kip
Journal:  Psychol Med       Date:  2021-05-12       Impact factor: 7.723

10.  Presynaptic GABAB receptor inhibition sex dependently enhances fear extinction and attenuates fear renewal.

Authors:  Jordan M Adkins; Joseph Lynch; Michael Gray; Aaron M Jasnow
Journal:  Psychopharmacology (Berl)       Date:  2021-04-14       Impact factor: 4.415

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.